GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    S. Karger AG ; 2003
    In:  Cerebrovascular Diseases Vol. 15, No. Suppl. 2 ( 2003), p. 49-55
    In: Cerebrovascular Diseases, S. Karger AG, Vol. 15, No. Suppl. 2 ( 2003), p. 49-55
    Type of Medium: Online Resource
    ISSN: 1421-9786 , 1015-9770
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2003
    detail.hit.zdb_id: 1482069-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cerebrovascular Diseases, S. Karger AG, Vol. 47, No. 3-4 ( 2019), p. 171-177
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Collateral circulation may modify the effect of neuroprotective therapies. We report a post hoc analysis of the URICO-ICTUS trial (NCT00860366) assessing the modifying treatment effect of pretreatment collaterals on clinical and radiological outcomes in patients with large-vessel acute ischemic stroke receiving uric acid therapy or placebo. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 URICO-ICTUS was a randomized clinical trial where 411 alteplase-treated patients also received uric acid 1,000 mg ( 〈 i 〉 n 〈 /i 〉 = 211) or placebo ( 〈 i 〉 n 〈 /i 〉 = 200) before the end of alteplase infusion. Herein, we included a nested study of 84 patients (placebo = 40, uric acid = 44) who had a pretreatment CT-angiography (CTA) showing a proximal arterial occlusion in the carotid territory. Excellent collaterals were defined as 100% collateral supply on pretreatment CTA. Regression models assessed the interaction between therapy (uric acid/placebo) and collaterals on the main outcome (ordinal modified Rankin Scale [mRS] shift at 90 days). 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Overall, excellent collaterals were associated with improved outcome. There was a significant interaction between therapy and pretreatment collaterals ( 〈 i 〉 p 〈 /i 〉 interaction = 0.02) for the prediction of improved mRS shift. The largest treatment contrast in favor of uric acid was found in patients with excellent collaterals (adjusted OR 9.2; 95% CI 1.23–68.6; 〈 i 〉 p 〈 /i 〉 = 0.03). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Collectively, the study found that collaterals were associated with the neuroprotective effect of uric acid therapy highlighting the importance of assessing collateral status in neuroprotection trials.
    Type of Medium: Online Resource
    ISSN: 1015-9770 , 1421-9786
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2019
    detail.hit.zdb_id: 1482069-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cerebrovascular Diseases, S. Karger AG, Vol. 49, No. 5 ( 2020), p. 550-555
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 The evolution of the symptomatic intracranial occlusion during transfers from primary stroke centers (PSCs) to comprehensive stroke centers (CSCs) for endovascular treatment (EVT) is not widely known. Our aim was to identify factors related to partial or complete recanalization (REC) at CSC arrival in patients with a documented large vessel occlusion (LVO) in PSC transferred for EVT evaluation to better define the workflow at CSC of this group of patients. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We conducted an observational, multicenter study from a prospective, government-mandated, population-based registry of stroke patients with documented LVO at PSC transferred to CSC for EVT from January 2017 to June 2019. The primary end point was defined as partial or complete REC that precluded EVT at CSC arrival (REC). We evaluated the association between baseline, treatment variables and time intervals with the presence of REC. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 From 589 patients, the rate of REC at CSC was 10.5% in all LVO patients transferred from PSC to CSC for EVT evaluation. On univariate analysis, lower PSC-NIHSS (median 12vs.16, 〈 i 〉 p 〈 /i 〉 = 0.001), tPA treatment at PSC (13.7 vs. 5.0%; 〈 i 〉 p 〈 /i 〉 = 0.001), presence of M2 occlusion on PSC (16.8 vs. 9%; 〈 i 〉 p 〈 /i 〉 = 0.023), and clinical improvement at CSC arrival (21.7 vs. 9.6% 〈 i 〉 p 〈 /i 〉 = 0.001) were associated with REC at CSC. On multivariate analysis, clinical improvement at CSC arrival ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001, OR: 5.96 95% CI: 2.5–13.9) and PSC tPA treatment predicted REC ( 〈 i 〉 p 〈 /i 〉 = 0.003, OR: 4.65, 95% CI: 1.73–12.4). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 REC at CSC arrival occurs exceptionally in patients with a documented LVO on PSC. Repeating a second vascular study before EVT would not be necessary in most patients. Despite its modest effect, tPA treatment at PSC was an independent predictor of REC.
    Type of Medium: Online Resource
    ISSN: 1015-9770 , 1421-9786
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2020
    detail.hit.zdb_id: 1482069-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cerebrovascular Diseases, S. Karger AG, Vol. 23, No. 2-3 ( 2007), p. 85-90
    Abstract: 〈 i 〉 Background: 〈 /i 〉 To determine the frequency and predictors of symptomatic intracerebral hemorrhage (SICH) in patients treated with recombinant tissue plasminogen activator (rt-PA). 〈 i 〉 Methods: 〈 /i 〉 We reviewed the databases of 7 tertiary hospitals that treated ischemic stroke patients with intravenous rt-PA. We recorded demographic data, vascular risk factors, time between onset and treatment, dose, the NIHSS score, body temperature, blood pressure, platelet count, blood glucose, antiplatelet treatment, and CT data. We also registered the study protocol used for treatment and deviations from the accepted protocol. A control CT was performed on all patients. SICH was diagnosed if a parenchymal hematoma was detected within the 36 h after rt-PA and was associated with an increase of ≧4 in the NIHSS score. Bivariate analyses were performed followed by a logistic regression analysis. 〈 i 〉 Results: 〈 /i 〉 A total of 347 patients were studied, whose mean age was 68 ± 10.9 years; 56% were men. Thirty-two patients (9.2%) exhibited a parenchymal hematoma, and 8 patients (2.3%) suffered a SICH. Patients with SICH had a higher frequency of previous transient ischemic attack (p = 0.04), early signs of ischemia (p = 0.003), hyperdense arterial sign (p = 0.008), and deviations (p = 0.002). Early signs of ischemia (OR 8.5, 95% CI 1.6–45.4, p = 0.01) and deviation from the protocol (OR 11.1, 95% CI 2.4–50, p = 0.002) were independent predictors of SICH. 〈 i 〉 Conclusions: 〈 /i 〉 SICH is infrequent in patients with ischemic stroke treated with rt-PA outside of a clinical trial. Its frequency increases in the presence of early signs of ischemia on the noncontrast CT scan and deviations from the recommended protocol.
    Type of Medium: Online Resource
    ISSN: 1015-9770 , 1421-9786
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2007
    detail.hit.zdb_id: 1482069-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cerebrovascular Diseases, S. Karger AG, Vol. 29, No. 6 ( 2010), p. 528-537
    Abstract: 〈 i 〉 Background: 〈 /i 〉 Variants in the 5-lipoxygenase-activating protein 〈 i 〉 (ALOX5AP) 〈 /i 〉 and phosphodiesterase 4D 〈 i 〉 (PDE4D) 〈 /i 〉 genes have first been associated with ischemic stroke (IS) through whole-genome linkage screens. However, association studies obtained conflicting results. We aimed to investigate the contribution of selected single nucleotide polymorphisms (SNPs) in these genes for the first time in a large Iberian population. 〈 i 〉 Methods: 〈 /i 〉 A case-control design was used to analyze one SNP in 〈 i 〉 ALOX5AP 〈 /i 〉 and five SNPs in 〈 i 〉 PDE4D 〈 /i 〉 in a total of 1,092 IS patients and 781 healthy controls of two different subsets from Spain and Portugal. The analysis was adjusted for confounding variables and the results were integrated in a meta-analysis of all case-control studies. In addition, 〈 i 〉 ALOX5AP 〈 /i 〉 gene expression levels were determined in controls and IS cases. 〈 i 〉 Results: 〈 /i 〉 A first meta-analysis of both subsets showed that the T allele of the SG13S114 SNP in 〈 i 〉 ALOX5AP 〈 /i 〉 was a risk factor for IS after Bonferroni correction [OR = 1.22 (1.06–1.40); p = 0.006]. A second meta-analysis of white populations confirmed these results [OR = 1.18 (1.07–1.31); p = 0.001] . 〈 i 〉 ALOX5AP 〈 /i 〉 gene expression analysis in a subset of controls and cases revealed that the SG13S114 genotypes modulate mRNA levels of 〈 i 〉 ALOX5AP 〈 /i 〉 (p = 0.001) and mRNA levels were higher in IS cases (2.8 ± 2.4%) than in controls (1.4 ± 1.3%; p = 0.003). No association of the variants in 〈 i 〉 PDE4D 〈 /i 〉 with IS was observed in our study. 〈 i 〉 Conclusions: 〈 /i 〉 The 〈 i 〉 ALOX5AP 〈 /i 〉 SG13S114 variant is an independent risk factor for IS in the Iberian population and is associated with 〈 i 〉 ALOX5A 〈 /i 〉 P expression levels. The role of this gene in stroke merits further investigation.
    Type of Medium: Online Resource
    ISSN: 1015-9770 , 1421-9786
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2010
    detail.hit.zdb_id: 1482069-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...